McAfee’s ‘Falcon’ to Come in Four Flavours

McAfee has something up their sleeve with their new “falcon” suite of security applications. According to ZDNet Australia, is appears that ”falcon” will come in four flavours.

The four editions will vary in the number of security features, giving consumers the option to buy a less comprehensive package. Offering various editions also allows McAfee to try to sell its customers a more expensive option at a premium price. Microsoft’s OneCare and Symantec’s Norton 360 are pitched as one size fits all.

Marc Solomon, director of product management at McAfee, said in an interview that all four McAfee products would include the basic security features — antivirus, anti-spyware and a firewall. Additionally, all editions include SiteAdvisor, which adds ratings to Web search results, and PC health tools for tasks such as hard drive defragmentation, he said.

McAfee has some decent basic security software that is good both at home and in an enterprise environment. It should be interesting to see where this new suite will fit in to their current offering.

McAfee Buys Risk Management Firm

McAfee has been out purchasing quite a few companies these days, in order to build up their information security arsenal. Today they snatched up a risk management firm that aims to protect large businesses.

McAfee on Tuesday said it had acquired Preventsys, a company that specializes in security risk management and compliance. The technology will be integrated into McAfee’s solutions for large businesses in order to protect customer information and communicate security compliance to executives.

“With Preventsys technology, we can help our customers satisfy regulatory requirements for automated compliance reporting, while leveraging existing McAfee technologies such as McAfee ePolicy Orchestrator and Foundstone,” said Ken Gonzalez, McAfee’s vice president of corporate development. Terms of the deal were not disclosed.

Looks to be a win-win situation for all involved. Since McAfee specifically speaks about ePO, I wonder exactly what else they plan to add to this already monstrous behemoth.